ENTITY

BeiGene (688235 CH)

45
Analysis
Health CareChina
BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.
more
18 May 2025 10:15

A-H Premium Weekly (May 16th): Cosco Shipping Development, Qingdao Port International

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Cosco Shipping Development, Qingdao Port International,...

Logo
460 Views
Share
15 May 2025 12:17

Jiangsu Hengrui Pharma A/H Listing - Low-End Is Probably Close to Fair Value

Jiangsu Hengrui Medicine (600276 CH), a China-based pharmaceutical company, aims to raise around US$1.3bn in its H-share listing. In this note, we...

Logo
634 Views
Share
11 May 2025 10:10

A-H Premium Weekly (May 9th): Datang Intl Power Gen, Beigene, CSSC O&M Engineering

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Datang Intl Power Gen, Beigene, CSSC O&M Engineering, Xinhua...

Logo
312 Views
Share
bullishBeiGene
11 May 2025 09:32

China Healthcare Weekly (May11)-Trump's Executive Order, Pharmacy's Risks, BeiGene 25Q1 Result Is Ok

​Trump aims to boost US drug manufacturing by reducing regulatory barriers, leading to industry changes. VBP will accelerate pharmacy closures....

Logo
630 Views
Share
08 May 2025 09:48

Jiangsu Hengrui Pharma A/H Listing - PHIP Updates and Updated Thoughts on A/H Premium

Jiangsu Hengrui Medicine (600276 CH) (JHP), a China-based pharmaceutical company, aims to raise around US$2bn in its H-share listing. In this note,...

Logo
423 Views
Share
x